NurExone Biologic: ExoPTEN and ExoTop, Advancing in Parallel

Two tracks, two opportunities

The standard preclinical biotech is built around a single therapeutic program. All value creation depends on that one drug candidate reaching human trials, then regulatory approval, then commercial launch. The model works, and the sector's biggest exits have all been built exactly that way. It also means single-track companies are typically valued as a function of one program's probability of success.

Look across the spinal cord injury landscape and the pattern is consistent. NervGen Pharma Inc. is advancing NVG-291, a peptide therapy currently in a Phase 3 trial for chronic SCI. Lineage Cell Therapeutics is advancing OPC1, a cell-based therapy for acute SCI. Look across the broader exosome therapeutics landscape and the same pattern holds: Aegle Therapeutics is running a Phase 1/2 study of AGLE-102 for severe burns; Capricor Therapeutics is developing CAP-2003 for inflammatory and fibrotic disorders. Each of these companies is single-track. Each has one primary therapeutic program driving the equity value.

NurExone is a preclinical biotech, but it is not a single-track company. It is advancing two commercially distinct businesses in parallel (a therapeutic drug program called ExoPTEN and a commercial exosome supply business called ExoTop), each with its own market, its own timeline, and its own value creation opportunity.

Track one: ExoPTEN, the therapeutic

The primary track is the drug program. ExoPTEN is NurExone's lead therapeutic candidate, an exosome-based nanodrug designed to deliver a small interfering RNA (siRNA) that silences the PTEN gene, which normally blocks nerve regeneration. In preclinical animal studies of complete spinal cord transection, minimally invasive ExoPTEN administration was associated with significant motor improvement, sensory recovery, and measurable nerve regeneration. In August 2026, NurExone reported statistically significant increases in myelin-positive cells in treated versus control animal models, adding another specific biological signal to the preclinical evidence base.

ExoPTEN holds Orphan Drug Designation from both the FDA and the EMA for acute spinal cord injury. Dual designations across the two largest pharmaceutical markets are unusual for a company of NurExone's size. Orphan Drug Designation indicates validated plausibility of the approach and provides regulatory incentives including potential market exclusivity upon approval but does not guarantee clinical success or approval.

The near-term regulatory milestone on this track is an Investigational New Drug (IND) submission targeted for the first half of 2027. In August 2026, NurExone locked in the manufacturing partner supporting that submission: a binding memorandum of understanding with U.S.-based Made Scientific, Inc. covering exclusive U.S. GMP manufacturing and commercial exosome supply, with first GMP exosome batches targeted for the same H1 2027 window. The Made Scientific MOU is binding but a definitive agreement has not yet been signed.

ExoPTEN is the track carrying the highest potential value on approval. It targets an indication with no existing regenerative treatment, in a category where the biological problem (nerve regeneration in the central nervous system) has been considered one of the hardest challenges in medicine. Dual FDA and EMA orphan drug status establishes a defined regulatory path in the two largest pharmaceutical markets, and a first-in-class exosome-based mechanism gives the program a distinctive scientific position. As with any preclinical program, ExoPTEN also carries the risk profile that comes with human trials that have not yet begun.

Where ExoPTEN sits in the SCI competitive landscape is worth understanding on its own. NervGen's NVG-291 is further along the clinical path, having reported positive topline data from the chronic cohort of its Phase 1b/2a trial and moved into a Phase 3 study. Lineage Cell Therapeutics' OPC1 approaches the same clinical problem through cell-based therapy that requires surgical delivery of oligodendrocyte progenitor cells into the injured cord. ExoPTEN's approach, an exosome delivery vehicle carrying a gene-silencing payload administered minimally invasively, is a distinctly different modality attempting to address the same underlying clinical need. All three programs are still working through fundamental clinical validation.

Track two: ExoTop, the commercial business

The second track is different in kind.

NurExone's U.S. subsidiary Exo-Top Inc. is not developing a drug candidate. It is building a commercial business selling naïve (unmodified) mesenchymal stem cell-derived exosomes to third parties across multiple end markets. The buyers span biotech companies and academic research groups using naïve exosomes for their own therapeutic and preclinical work, and manufacturers in the beauty and longevity segments incorporating exosomes into skincare, hair, regenerative, and anti-aging product lines. Naïve exosome demand in the beauty and longevity markets is a distinct, non-clinical revenue channel that does not depend on the same regulatory pathway as therapeutic products.

The ExoTop commercial framework moved into its first meaningful contract in June 2026. On June 24, 2026, Exo-Top signed a binding memorandum of understanding with ExoLyra LLC for a proposed distribution agreement in Mexico. The proposed structure includes exclusive rights to market, import, and sell specified naïve MSC-derived exosome products in Mexico for an initial three-year term, supported by a US$180,000 territorial exclusivity fee and minimum purchase commitments. The MOU is binding but a definitive distribution agreement has not yet been signed. Revenue is not yet material.

ExoTop's opportunity is real on its own terms. Naïve exosome demand is expanding rapidly across the beauty, longevity, and biotech supply markets, and consistent GMP-grade supply of high-quality exosomes has been one of the category's structural bottlenecks. ExoTop is positioning itself to sit inside that gap. Every additional distribution agreement Exo-Top signs, and every additional country in the ExoTop footprint, adds a revenue stream on a commercial timeline that runs in parallel with the therapeutic program.

This is where the dual-track structure separates NurExone from other exosome-focused biotechs. Aegle Therapeutics and Capricor Therapeutics are each developing exosome-based therapeutic programs, but neither operates a parallel commercial exosome supply business at scale. NervGen and Lineage Cell Therapeutics, working on the same SCI clinical problem NurExone is targeting, do not have a commercial exosome business at all because they do not operate in the exosome category. The commercial channel through ExoTop is not the industry default. It is a deliberate structural choice that gives NurExone a second, non-clinical route to revenue that its therapeutic-focused peers do not have.

Why the parallel structure matters

Running the two tracks in parallel is a structural choice with three specific consequences for how NurExone's business compounds over time.

First, the two tracks share underlying manufacturing infrastructure. The Made Scientific U.S. GMP capacity coming online for the therapeutic program is the same category of GMP capacity that ExoTop's commercial customers require. Investment in one track directly produces manufacturing capability the other track uses, and the same supply chain serves both.

Second, the two tracks reinforce the same commercial and scientific brand. Every ExoTop distribution agreement establishes NurExone as a credible commercial exosome partner in a specific jurisdiction. Every ExoPTEN preclinical result reinforces NurExone's scientific credibility in the broader exosome category. The two build the company's market position together.

Third, the two tracks operate on independent timelines. ExoPTEN's value creation runs on the regulatory clock: IND, then human trials, then approval. ExoTop's value creation runs on the commercial clock: distribution agreements, orders, delivery. Both timelines are live at the same time, and each track can produce meaningful milestones while the other advances.

What comes next on both tracks

Both tracks have real work ahead with a key, joint element being execution of a definitive agreement with Made Scientific and initiation of first GMP exosome batches in H1 2027. ExoPTEN’s near term milestone is the IND submission itself. For ExoTop, execution of the ExoLyra definitive distribution agreement, additional country-level distribution agreements, and the ramp of first commercial exosome deliveries are the near-term milestones. As with any preclinical program, the vast majority of preclinical drug candidates do not reach regulatory approval, and commercial arrangements can slip or be modified. Structural differentiation from the standard single-track model does not guarantee clinical or commercial outcomes; peers with more advanced clinical data (NervGen's NVG-291 is a clear example) or larger commercial infrastructure may execute faster on their own tracks.

What makes NurExone worth understanding is that the shape of the business is not the shape of a typical single-track preclinical biotech. Two distinct opportunities are being advanced in parallel, each on its own merits, each with its own path to value creation. That structure is uncommon in the sector, and it is worth taking the time to understand before drawing conclusions about how to evaluate NurExone against its peers.

The tickers are NRX on the TSX Venture Exchange, NRXBF on the U.S. OTCQB, and J90 on the Frankfurt Stock Exchange. For additional information, visit nurexone.com or public filings on SEDAR+.

Disclaimer: This content has been paid for by NurExone Biologic Inc. Cashu Group was compensated by NurExone Biologic Inc. for the creation and distribution of this content. The author is not a registered investment advisor or medical professional. NurExone's products are in the preclinical stage and have not been tested in humans or approved by any regulatory authority. All financial figures, scientific claims, pipeline details, and company data referenced come from NurExone Biologic Inc.'s public disclosures, press releases, and SEDAR+ filings. Preclinical results referenced are from animal studies and do not guarantee similar outcomes in humans. Orphan Drug Designations referenced provide regulatory incentives including potential market exclusivity upon approval but do not guarantee clinical success, regulatory approval, or commercial viability. The Made Scientific memorandum of understanding referenced is a binding MOU, not a completed definitive agreement; if the parties do not execute a definitive agreement within six months of MOU execution, the MOU and its exclusivity obligations automatically terminate. The ExoLyra memorandum of understanding referenced is a binding MOU for a proposed distribution agreement; a definitive distribution agreement has not yet been signed. Private placements completed in June and August 2026 resulted in additional share issuance and dilution to existing shareholders. References to other companies in the spinal cord injury and exosome therapeutics pipelines (including NervGen Pharma Inc., Lineage Cell Therapeutics, Aegle Therapeutics, and Capricor Therapeutics) are descriptive of the competitive landscape and are not comparisons implying equivalent clinical or commercial outcomes for NurExone. References to prior work by team members at other companies are historical and are not an indication of future performance at NurExone Biologic. The ExoTop naïve exosome commercial business is at an early stage and no anticipated revenue level is guaranteed; commercial arrangements referenced (including the ExoLyra Mexico MOU) may not produce anticipated revenues on the timelines currently disclosed. Investing in preclinical biotech companies involves significant risk, including the possible loss of all capital invested. The majority of preclinical drug candidates never achieve regulatory